External Trigeminal Neurostimulation In Patients with Chronic Migraine

References

• Ashina M . Migraine. Engl. J. Med.383(19), 1866–1876 (2009).
   Google Scholar
• Lipton RB , BigalME , DiamondM. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology68, 343–349 (2007).
   PubMed Web of Science ®Google Scholar
• Baigi K , StewartWF. Headache and migraine: a leading cause of absenteeism. Handb. Clin. Neurol.131, 447–463 (2015).
   PubMedGoogle Scholar
• Headache Classification Committee of the International Headache Society (IHS) . The International Classification of Headache Disorders, 3rd edition. Cephalalgia38, 1–211 (2018).
   PubMed Web of Science ®Google Scholar
• Diener HC , HolleD , SolbachKet al. Medication-overuse headache: risk factors, pathophysiology and management. Nat. Rev. Neurol.12, 575–583 (2016).
   PubMed Web of Science ®Google Scholar
• Natoli J , ManackA , DeanBet al. Global prevalence of chronic migraine: a systematic review. Cephalalgia30, 599–609 (2010).
   PubMed Web of Science ®Google Scholar
• Evers S , MarziniakM. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol.9, 391–401 (2019).
   Google Scholar
• Silberstein SD , HollandS , FreitagFet al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards Subcommittee of the American Academy of neurology and the American headache society. Neurology17, 1337–1345 (2012).
   Google Scholar
• Martelletti P . The therapeutic armamentarium in migraine is quite elderly. Expert Opin. Drug Metab. Toxicol.11, 175–177 (2015).
   PubMed Web of Science ®Google Scholar
• Luykx J , MasonM , FerrariMD , CarpayJ. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate related adverse drug reactions in epilepsy and migraine. Clin. Pharmacol. Ther.85, 283–288 (2009).
   PubMed Web of Science ®Google Scholar
• Berger A , BloudekLM , VaronSF , OsterG. Adherence with migraine prophylaxis in clinical practice. Pain Pract.12, 541–549 (2012).
   PubMed Web of Science ®Google Scholar
• Aurora SK , DodickDW , TurkelCCet al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia30, 793–803 (2010).
   PubMed Web of Science ®Google Scholar
• Diener HC , DodickDW , AuroraSKet al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia30, 804–814 (2010).
   PubMed Web of Science ®Google Scholar
• Sacco S , BendtsenL , AshinaMet al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain20, 6 (2019).
   PubMed Web of Science ®Google Scholar
• Martelletti P . Erenumab is effective in reducing migraine frequency and improving physical functioning. BMJ Evid. Based Med.24, 76 (2019).
   PubMedGoogle Scholar
• Magis D , SchoenenJ. Advances and challenges in neurostimulation for headaches. Lancet Neurol.11, 708–719 (2012).
   PubMed Web of Science ®Google Scholar
• D’Ostilio K , MagisD. Invasive and non-invasive electrical pericranial nerve stimulation for the treatment of chronic primary headaches. Curr. Pain Headache Rep.20, 61 (2016).
   PubMed Web of Science ®Google Scholar
• Schoenen J , VandersmissenB , JeangetteSet al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology80, 697–704 (2013).
   PubMed Web of Science ®Google Scholar
• Noseda R , BursteinR. Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, cortical spreading depression, sensitization, and modulation of pain. Pain154, S44–S53 (2013).
   PubMed Web of Science ®Google Scholar
• Bartsch T , GoadsbyPJ. The trigeminocervical complex and migraine: current concepts and synthesis. Curr. Pain Headache Rep.7, 371–376 (2003).
   PubMedGoogle Scholar
• Matharu MS , BartschT , WardNet al. Central neuro-modulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain127, 220–230 (2004).
   PubMed Web of Science ®Google Scholar
• Schoenen J , VandersmissenB , JeangetteSet al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology80, 697–704 (2012).
   Web of Science ®Google Scholar
• Di Fiore P , BussoneG , GalliAet al. Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial. Neurol. Sci.38(Suppl. 1), S201–S206 (2017).
   Google Scholar
• Dworkin RH , TurkDC , WyrwichKWet al. Interpreting the clinical importance of treatment outcomes in Chronic Pain Clinical Trials: IMMPACT recommendations. J. Pain9, 105–121 (2008).
   PubMed Web of Science ®Google Scholar
• Yang M , Rendas-BaumR , VaronSF , KosinskiM. Validation of the headache impact test (HIT-6TM) across episodic and chronic migraine. Cephalalgia31, 357–367 (2011).
   PubMed Web of Science ®Google Scholar
• Tassorelli C , DienerHC , DodickDWet al. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia39, 687–710 (2019).
   PubMed Web of Science ®Google Scholar
• Italian Medicines Agency (AIFA). Pricing and reimbursement and monitoring registers. https://www.aifa.gov.it/en/-/modifica-registri-aimovig-ajovy-ed-emgality-emicrania (Accessed 30September2022).
   Google Scholar
• Sacco S , BendtsenL , AshinaMet al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J. Headache Pain20, 6 (2019).
   PubMed Web of Science ®Google Scholar
• American Headache Society . The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache59, 1–18 (2019).
   PubMed Web of Science ®Google Scholar
• Ferrari MD , GoadsbyPJ , BursteinRet al. Migraine. Nat. Rev. Dis. Primers8(1), 2 (2022).
   PubMed Web of Science ®Google Scholar
• Sacco S , BraschinskyM , DucrosAet al. European headache federation consensus on the definition of resistant and refractory migraine: developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J. Headache Pain21(1), 76 (2020).
   PubMed Web of Science ®Google Scholar
• Probyn K , BowersH , MistryDet al. Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components. BMJ Open7, e016670 (2017).
   PubMed Web of Science ®Google Scholar
• Speciali JG , PeresM , BigalME. Migraine treatment and placebo effect. Expert Rev. Neurother.10, 413–419 (2010).
   PubMed Web of Science ®Google Scholar
• Meissner K , FässlerM , RückerGet al. Differential effectiveness of placebo treatments. A systematic review of migraine prophylaxis. JAMA Intern. Med.173, 1941–1951 (2013).
   PubMed Web of Science ®Google Scholar